← The Wire
JANXNasdaq
Janux Therapeutics, Inc.
Pharmaceutical Preparations · DE · CIK 1817713
Developing novel immunotherapies using proprietary T cell engager and modulator platforms for cancer treatment
red 8-K · 90d
$827M
Market cap
$15.32
Last close
+2.6%
1D
+6.9%
5D
1.2M
Volume
Price · last 39 sessions+6.3%
May 4L $13.15 · H $15.32Jun 29
98
Total filings
Jun 23, 2026
Last filing
12/31
Fiscal year end
8-KCompany UpdateJun 23, 20268-KShareholder VoteJun 12, 202610-Q10-QMay 7, 20268-KResults of OperationsMay 7, 20268-KExecutive ChangeApr 28, 2026DEFA14ADEFA14AApr 28, 2026DEF 14ADEF 14AApr 28, 202610-K10-KFeb 26, 20268-KResults of OperationsFeb 26, 20268-KMaterial Agreement · Reg FD DisclosureJan 22, 202610-Q10-QNov 6, 20258-KResults of OperationsNov 6, 20258-KExecutive ChangeSep 19, 202510-Q10-QAug 7, 20258-KResults of OperationsAug 7, 20258-KShareholder VoteJun 13, 202510-Q10-QMay 8, 20258-KResults of OperationsMay 8, 2025DEFA14ADEFA14AApr 25, 2025DEF 14ADEF 14AApr 25, 202510-K10-KFeb 27, 20258-KResults of OperationsFeb 27, 20258-KCompany UpdateDec 5, 2024424B5424B5Dec 5, 2024424B5424B5Dec 3, 20248-KReg FD Disclosure · Company UpdateDec 2, 202410-Q10-QNov 6, 20248-KResults of OperationsNov 6, 2024SC 13GSC 13GOct 23, 202410-Q10-QAug 7, 20248-KResults of OperationsAug 7, 20248-KExecutive ChangeJul 22, 20248-KShareholder VoteJun 28, 2024DEFA14ADEFA14AJun 17, 202410-Q10-QMay 8, 20248-KResults of OperationsMay 8, 2024DEFA14ADEFA14AApr 29, 2024DEF 14ADEF 14AApr 29, 202410-K10-KMar 8, 20248-KResults of OperationsMar 8, 2024424B5424B5Feb 29, 20248-KCompany UpdateFeb 29, 20248-KCompany UpdateFeb 28, 2024424B5424B5Feb 28, 20248-KCompany UpdateFeb 27, 20248-KReg FD DisclosureFeb 26, 202410-Q10-QNov 7, 20238-KResults of OperationsNov 7, 202310-Q10-QAug 8, 20238-KResults of Operations · Company UpdateAug 8, 2023424B5424B5Jul 18, 20238-KMaterial Agreement · Company UpdateJul 18, 20238-KResults of Operations · Reg FD DisclosureJul 17, 2023SC 13GSC 13GJul 10, 20238-KExecutive ChangeJun 23, 20238-KDelisting Notice · Shareholder VoteJun 20, 2023SC 13GSCHEDULE 13GMay 30, 20238-KMaterial AgreementMay 9, 2023424B5424B5May 9, 202310-Q10-QMay 9, 20238-KResults of OperationsMay 9, 2023DEFA14ADEFA14AApr 28, 2023DEF 14ADEF 14AApr 28, 20238-KExecutive ChangeMar 31, 202310-K10-KMar 10, 20238-KResults of OperationsMar 10, 2023SC 13GSC 13GJan 23, 202310-Q10-QNov 10, 20228-KResults of OperationsNov 10, 20228-KExecutive ChangeSep 22, 202210-Q10-QAug 9, 20228-KResults of OperationsAug 9, 20228-KShareholder VoteJun 15, 202210-Q10-QMay 10, 20228-KResults of OperationsMay 10, 20228-KCompany UpdateMay 2, 2022DEFA14ADEFA14AApr 29, 2022DEF 14ADEF 14AApr 29, 202210-K10-KMar 18, 20228-KResults of OperationsMar 18, 2022
Insider Activity
In the 90 days to Jan 2, 2026: 6 sold $972K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 2, 2026 | Campbell David AlanPresident and CEO | Sell | 8,072 | $13.73 | $111K |
| Jan 2, 2026 | Mciver ZachariahChief Medical Officer | Sell | 2,714 | $13.73 | $37K |
| Jan 2, 2026 | Diraimondo ThomasChief Scientific Officer | Sell | 2,505 | $13.73 | $34K |
| Jan 2, 2026 | Winter Charles M.Chief Technical Officer | Sell | 2,401 | $13.73 | $33K |
| Jan 2, 2026 | Meyer Andrew HollmanChief Business Officer | Sell | 1,879 | $13.73 | $26K |
| Jan 2, 2026 | Dobek MariaVice President, Accounting | Sell | 1,462 | $13.73 | $20K |
| Dec 1, 2025 | Meyer Andrew HollmanChief Business Officer | Sell | 2,700 | $32.85 | $89K |
| Dec 1, 2025 | Meyer Andrew HollmanChief Business Officer | Sell | 633 | $33.52 | $21K |
| Nov 14, 2025 | Meyer Andrew HollmanChief Business Officer | Sell | 3,333 | $30.00 | $100K |
| Oct 28, 2025 | Meyer Andrew HollmanChief Business Officer | Sell | 16,665 | $30.06 | $501K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance